As per the research report titled ‘Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)’, available with MarketStudyReport, global Alzheimer drugs market which was worth USD 6537 million in 2021, is expected to record decent expansion during 2022-2027. 

Rising geriatric population, increasing prevalence of Alzheimer's disease among geriatric population, and an uptick in clinical trials & novel drug launches are attributes propelling global Alzheimer drugs market expansion.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4597183/

Furthermore, poor lifestyle preferences that lead to disease vulnerability, combined with the advent of effective therapies by crucial players that excel at providing long-term improvements in cognitive abilities are all accelerating industry development.

Aside from that, several Alzheimer's drugs, including Aducanumab and Solanezumab, are currently in late-stage clinical studies. Launch of these drugs is expected to steer the progress of the business sphere in the forthcoming years.

Notably, telehealth is the distant supply of clinical and non-clinical services via digital communication technologies. These portals have made early detection of disease and drug delivery possible in remote areas. Hence, widening popularity of online drugstores and telehealth consultations is positively swaying worldwide Alzheimer drugs market.

In terms of drug class, the market is categorized into memantine, cholinergic, combined drug, and others. Based on distribution channel, the online pharmacy vertical is estimated to register substantial growth during the forecast period, owing to the advent of online drugstores that enable precise disease diagnosis and offer ease delivery of medicines in remote locations. 

Concerning geographical terrain, North America (Canada, United States, Europe (France, Italy, Germany, UK, and Asia Pacific (India, Australia, Japan, China) are the major areas driving the revenue for overall industry. The report includes a thorough assessment of each region’s growth rate and performance potential, providing stakeholders a fair outlook on current dynamics to help them make well-informed decisions.

The notable firms in global Alzheimer drugs industry are Eli Lilly and Company, NervGen Pharma Corporation, Novo Nordisk A/S, Novartis International AG, Daichi Sankyo Company Limited, Biogen Inc., Takeda Pharmaceutical Company Limited., F. Hoffmann-La Roche AG, Eisai Co. Ltd., AbbVie Inc., and Pfizer Inc. among others.